Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca presents new data from Corona study

AstraZeneca presents new data from Corona study

7th November 2007

AstraZeneca has presented new data from its Corona study showing that optimised heart failure treatment did not significantly improve when patients with advanced heart failure were given statins.

Study data, announced at the American Heart Association 2007 Scientific Sessions in Orlando, found that adding a statin could not reverse or prevent the deterioration of a failing heart.

The results are part of the AstraZeneca’s Corona study which is designed to evaluate the effects of adding Crestor 10mg to optimised treatment on cardiovascular mortality and overall survival in patients.

It was found that patients taking Crestor (rosuvastatin) 10mg experienced a statistically insignificant eight per cent reduction in the combined primary endpoint of cardiovascular death or myocardial infarction or stroke.

The small percentage reduction was driven by a fall in atherosclerotic events, ie stroke and myocardial infarctions, which statins have shown to have a benefit.

However the majority of deaths were due to sudden death, or non-ischemic causes, which is not shown to be affected by statin therapy.

Commenting on the results, Professor of John Kjekshus from the Department of Cardiology at University Hospital Oslo, stated: “Our findings suggest the major cause of death in these patients was likely not to be related to atherosclerotic events, where benefit with statins in non-heart failure patients has been demonstrated, but instead may have been caused by the deterioration of failing heart muscle damaged beyond repair.”

Last week, AstraZeneca confirmed that Crestor faced a patent challenge from Canadian company Cobalt pharmaceuticals.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.